Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Research & Development (2017 - 2025)

Puma Biotechnology's Research & Development history spans 9 years, with the latest figure at $16.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 11.02% year-over-year to $16.8 million; the TTM value through Dec 2025 reached $62.1 million, up 12.98%, while the annual FY2025 figure was $62.1 million, 12.98% up from the prior year.
  • Research & Development reached $16.8 million in Q4 2025 per PBYI's latest filing, up from $15.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.2 million in Q1 2021 to a low of $7.0 million in Q3 2022.
  • Average Research & Development over 5 years is $14.4 million, with a median of $13.8 million recorded in 2022.
  • Peak YoY movement for Research & Development: tumbled 62.84% in 2022, then skyrocketed 63.51% in 2023.
  • A 5-year view of Research & Development shows it stood at $14.2 million in 2021, then fell by 2.71% to $13.8 million in 2022, then fell by 6.61% to $12.9 million in 2023, then rose by 17.84% to $15.2 million in 2024, then grew by 11.02% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Research & Development are $16.8 million (Q4 2025), $15.9 million (Q3 2025), and $15.5 million (Q2 2025).